259 related articles for article (PubMed ID: 8830951)
1. Gating of auditory P50 in schizophrenics: unique effects of clozapine.
Nagamoto HT; Adler LE; Hea RA; Griffith JM; McRae KA; Freedman R
Biol Psychiatry; 1996 Aug; 40(3):181-8. PubMed ID: 8830951
[TBL] [Abstract][Full Text] [Related]
2. Varied effects of atypical neuroleptics on P50 auditory gating in schizophrenia patients.
Adler LE; Olincy A; Cawthra EM; McRae KA; Harris JG; Nagamoto HT; Waldo MC; Hall MH; Bowles A; Woodward L; Ross RG; Freedman R
Am J Psychiatry; 2004 Oct; 161(10):1822-8. PubMed ID: 15465979
[TBL] [Abstract][Full Text] [Related]
3. Dopaminergic modulation of the P50 auditory-evoked potential in a computer model of the CA3 region of the hippocampus: its relationship to sensory gating in schizophrenia.
Moxon KA; Gerhardt GA; Adler LE
Biol Cybern; 2003 Apr; 88(4):265-75. PubMed ID: 12690485
[TBL] [Abstract][Full Text] [Related]
4. Antipsychotic effects on auditory sensory gating in schizophrenia patients.
Sánchez-Morla EM; Santos JL; Aparicio A; García-Jiménez MA; Villanueva C; Martínez-Vizcaíno V; Arango C
Eur Neuropsychopharmacol; 2009 Dec; 19(12):905-9. PubMed ID: 19833483
[TBL] [Abstract][Full Text] [Related]
5. Auditory P50 in schizophrenics on clozapine: improved gating parallels clinical improvement and changes in plasma 3-methoxy-4-hydroxyphenylglycol.
Nagamoto HT; Adler LE; McRae KA; Huettl P; Cawthra E; Gerhardt G; Hea R; Griffith J
Neuropsychobiology; 1999; 39(1):10-7. PubMed ID: 9892854
[TBL] [Abstract][Full Text] [Related]
6. Normal P50 suppression in schizophrenia patients treated with atypical antipsychotic medications.
Light GA; Geyer MA; Clementz BA; Cadenhead KS; Braff DL
Am J Psychiatry; 2000 May; 157(5):767-71. PubMed ID: 10784470
[TBL] [Abstract][Full Text] [Related]
7. Neuroleptic effects on P50 sensory gating in patients with first-episode never-medicated schizophrenia.
Hong X; Chan RC; Zhuang X; Jiang T; Wan X; Wang J; Xiao B; Zhou H; Jiang L; Weng B
Schizophr Res; 2009 Mar; 108(1-3):151-7. PubMed ID: 19106034
[TBL] [Abstract][Full Text] [Related]
8. Clozapine improves deficient inhibitory auditory processing in DBA/2 mice, via a nicotinic cholinergic mechanism.
Simosky JK; Stevens KE; Adler LE; Freedman R
Psychopharmacology (Berl); 2003 Feb; 165(4):386-96. PubMed ID: 12459928
[TBL] [Abstract][Full Text] [Related]
9. P50 gating at acute and post-acute phases of first-episode schizophrenia.
Devrim-Uçok M; Keskin-Ergen HY; Uçok A
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Dec; 32(8):1952-6. PubMed ID: 18929611
[TBL] [Abstract][Full Text] [Related]
10. Neurophysiological evidence for a defect in inhibitory pathways in schizophrenia: comparison of medicated and drug-free patients.
Freedman R; Adler LE; Waldo MC; Pachtman E; Franks RD
Biol Psychiatry; 1983 May; 18(5):537-51. PubMed ID: 6134559
[TBL] [Abstract][Full Text] [Related]
11. Gender differences in neuroleptic nonresponsive clozapine-treated schizophrenics.
Szymanski S; Lieberman J; Pollack S; Kane JM; Safferman A; Munne R; Umbricht D; Woerner M; Masiar S; Kronig M
Biol Psychiatry; 1996 Feb; 39(4):249-54. PubMed ID: 8645771
[TBL] [Abstract][Full Text] [Related]
12. Changes in weight and body mass index during treatment with melperone, clozapine and typical neuroleptics.
Bobo WV; Jayathilake K; Lee MA; Meltzer HY
Psychiatry Res; 2010 Apr; 176(2-3):114-9. PubMed ID: 20199813
[TBL] [Abstract][Full Text] [Related]
13. [P50 component of auditory evoked potentials in persons with schizophrenia and their first degree relatives].
Wegrzyn J; Wciórka J
Psychiatr Pol; 2004; 38(3):395-408. PubMed ID: 15199650
[TBL] [Abstract][Full Text] [Related]
14. Differential effects of clozapine versus other antipsychotics on clinical outcome and dopamine release in the brain.
Advokat C
Essent Psychopharmacol; 2005; 6(2):73-90. PubMed ID: 15765792
[TBL] [Abstract][Full Text] [Related]
15. Effects of clozapine on smoking in chronic schizophrenic outpatients.
George TP; Sernyak MJ; Ziedonis DM; Woods SW
J Clin Psychiatry; 1995 Aug; 56(8):344-6. PubMed ID: 7635849
[TBL] [Abstract][Full Text] [Related]
16. Clozapine, but not typical antipsychotics, correct P50 suppression deficit in patients with schizophrenia.
Becker J; Gomes I; Ghisolfi ES; Schuch A; Ramos FL; Ehlers JA; Nora DB; Lara DR; da Costa JC
Clin Neurophysiol; 2004 Feb; 115(2):396-401. PubMed ID: 14744582
[TBL] [Abstract][Full Text] [Related]
17. Effects of clozapine on perceptual abnormalities and sensory gating: a preliminary cross-sectional study in schizophrenia.
Micoulaud-Franchi JA; Aramaki M; Geoffroy PA; Richieri R; Cermolacce M; Faget C; Ystad S; Kronland-Martinet R; Lancon C; Vion-Dury J
J Clin Psychopharmacol; 2015 Apr; 35(2):184-7. PubMed ID: 25587694
[TBL] [Abstract][Full Text] [Related]
18. [Atypical neuroleptics and selective attention].
Stip E; Lussier I; Lalonde P; Luyet A; Fabian J
Encephale; 1999; 25(3):260-4. PubMed ID: 10434152
[TBL] [Abstract][Full Text] [Related]
19. Early developmental differences between DSM-III-R schizophrenics treated with clozapine and typical neuroleptics.
Mäkikyrö T; Leinonen E; Koponen H; Järvelin MR; Hakko H; Saarnisaari O; Isohanni M
J Psychiatr Res; 1998; 32(2):105-10. PubMed ID: 9694006
[TBL] [Abstract][Full Text] [Related]
20. Sensory gating deficits in parents of schizophrenics.
Waldo M; Myles-Worsley M; Madison A; Byerley W; Freedman R
Am J Med Genet; 1995 Dec; 60(6):506-11. PubMed ID: 8825886
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
